Welcome to the ProFactor Pharma website.
ProFactor Pharma Ltd (PFP) was established to commercialise and supply recombinant blood factors for the treatment of haemophilia to a severely undersupplied world market to make more product available to treat more patients.
According to the World Health Organisation (WHO) almost three quarters of the haemophilia patient population receive inadequate or no treatment at all.
We ask, “why is that?”
Unmet Market demand is locked out by high prices and limited supply. PFP addresses both these issues with a PFP Higher yielding process delivering substantially lower cost of goods.
PFP’s objective is to serve a valuable market ‘others cannot reach’, delivering recombinant Factor VIII at reduced cost to haemophilia patients and health care providers, generating significant profitability and providing an excellent return to shareholders.